Skip to main content
Clinical Trials/EUCTR2020-001449-38-GB
EUCTR2020-001449-38-GB
Active, Not Recruiting
Phase 1

A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe - PIONEER

Chelsea and Westminster Hospital NHS Foundation Trust0 sites450 target enrollmentApril 17, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
COVID-19 Infection
Sponsor
Chelsea and Westminster Hospital NHS Foundation Trust
Enrollment
450
Status
Active, Not Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 17, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Chelsea and Westminster Hospital NHS Foundation Trust

Eligibility Criteria

Inclusion Criteria

  • he participant may enter the study if the following apply:
  • 1\.Adult participants: Signed informed consent
  • 2\.New admission to hospital for period expected to last \= 1 night
  • 3\.Suspected or confirmed COVID\-19 infection
  • Patients are suspected of COVID\-19 infection if they have one of the following:
  • ·Influenza like illness (fever \=37\.8°C and at least one of the following respiratory symptoms, which must be of acute onset: persistent cough, hoarseness, nasal discharge or congestion, shortness of breath, sore throat, wheezing or sneezing).
  • ·Acute respiratory distress syndrome
  • ·Radiological evidence of pneumonia
  • 4\.For women to be eligible to enter and participate in the study they should be: of non\-child\-bearing
  • \-potential defined as either post\-menopausal (12 months of spontaneous amenorrhea and \= 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,

Exclusion Criteria

  • The participant may not enter the study if ANY of the following apply:
  • 1\.Pregnant or breast feeding, due to potential teratogenicity
  • 2\.Hepatic impairment – (AST or ALT \> 3\.5 x upper limit of normal)
  • 3\.Renal impairment – (eGFR \<10ml/ minute)
  • 4\.Known history of retinopathy
  • 5\.Known history of G6PD deficiency
  • 6\.Known history of Myasthenia gravis
  • 7\.QT\-prolongation (\>430ms in males or \>450ms in females, calculated as per investigators discretion)
  • 8\.Presently enrolled in an interventional drug study or on hydroxychloroquine or azithromycin for other therapeutic reasons
  • 9\.Unable to take medication via the oral or nasogastric route

Outcomes

Primary Outcomes

Not specified

Similar Trials